• Explore /
  • Poster
  • / Phase I dose escalation study of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis.

Phase I dose escalation study of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis.

Abstract Poster

Authors

null

Bruno Sangro

Clinica Universidad de Navarra and CIBEREHD, Pamplona, Spain

Bruno Sangro , Todd S. Crocenzi , Theodore Hobart Welling III, Mercedes Iñarrairaegui , Jesús Prieto , Carmen Fuertes , Laurie Delanty , William Feely , Jeffrey Anderson , Dennis M. Grasela , Jon M. Wigginton , Ashok Kumar Gupta , Ignacio Melero

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics - Immunotherapy

Track

Developmental Therapeutics

Sub Track

Immunotherapy and Biologic Therapy

Clinical Trial Registration Number

NCT01658878

Citation

J Clin Oncol 31, 2013 (suppl; abstr TPS3111)

DOI

10.1200/jco.2013.31.15_suppl.tps3111

Abstract #

TPS3111

Poster Bd #

22F

Abstract Disclosures

Similar Posters

Poster

2017 Gastrointestinal Cancers Symposium

Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): The CheckMate 040 study.

Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): The CheckMate 040 study.

First Author: Ignacio Melero

First Author: Bruno Sangro

First Author: Laura Quan Man Chow

First Author: Arndt Vogel